Clinical Trial Management System Market - Global Growth Prospects

Market Dynamics:

Factors such as significant partnerships between biopharma companies and CROs, rising number of clinical trials, availability of advanced CTMS solutions, growing customer base for CTMS solutions, and rising government funding & grants to support clinical trials are driving the overall demand for CTMS across key markets.

However, budget constraints and limited awareness among researchers about the advantages of CTMS solutions are the major factors restraining the growth of CTMS market.

Driver: Rising number of clinical trials to drive the CTMS market

The life science industry is witnessing a global increase in the number of clinical trials each year.

This growth in the number of clinical trials conducted can be attributed to factors such as the rapidly increasing aging population, high prevalence of chronic diseases, expiry of blockbuster drugs, availability of government funds for clinical trials, and fierce competition in the pharmaceutical industry. According to ClinicalTrials.gov, as of December 06, 2017, 260,848 clinical trials were registered across the globe.

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=470

The global CTMS market is expected to reach $1,928.9 million by 2027 from $590.0 million in 2017, at a CAGR of 12.6%. The major factors driving the growth of the CTMS market include the significant partnerships between Asian CROs and pharma companies, rising number of clinical trials in both developing and developed nations, availability of advanced and upgraded CTMS solutions, and rising government support for clinical trials in Asian countries. 

Key questions addressed in the report:

# What are the growth opportunities related to CTMS market across major regions in the future?

# Emerging countries have immense opportunities for the growth and adoption of enterprise CTMS products. Will this scenario continue in the next five years?

# What are the various types of CTMS products and their market share in the overall market?

# What are the new trends and advancements in the clinical trials industry?

Restraint: Limited awareness among researchers about the advantages of CTMS solutions

Several investigators are either unaware or ignorant of the benefits of CTMS over traditional paper-based work or spreadsheets method. Clinical trial investigators need to understand the prospects of these tools which enhance the clinical trial process and help manage it effectively. This limited awareness in the research community is consequently limiting the adoption of CTMS solutions.

Recent Developments:

# In November 2017, Bio-Optronics and Complion entered into a partnership in order to integrate and develop their solutions, namely, CTMS and eRegulatory Solutions

# In September 2017, Pamplona completed the acquisition of Paraxel and bought its shares in order to help PARAXEL increase its productivity.

# In May 2017, Oracle opened its Oracle Cloud EU Region in Germany, with the addition of modern infrastructure as a service (IaaS) architecture and new IaaS and platform as a service (PaaS) cloud services.

# In January 2017, MedNet Solutions released the latest version of iMedNet with enhanced features

# In June 2016, Bio-Optronics launched the latest version of the Clinical Conductor CTMS.

Request Sample pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=470

North America is expected to dominate the CTMS market during the forecast period

Geographically, the CTMS market is segmented into North America, Europe, Asia Pacific, and the rest of the world. North America is expected to account for the largest share of the global CTMS market during the forecast period (2017-2027). Factors such as rising number of on-going clinical trials (especially in the US), presence of leading players from both demand and supply sides, and government funding for clinical research are contributing to the large share of the North American region.

The major players operating in the clinical trial management system market include Oracle (US), Medidata Solutions (US), PAREXEL (US), Bioclinica (US), Bio-Optronics (US), and IBM (US).

Analysis of the market developments between 2014 and 2017 revealed that several growth strategies such as product launches, enhancements, strategic acquisitions, agreements, partnerships, collaborations, and expansions were adopted by the market players to strengthen their product portfolios and maintain a competitive position in the CTMS market. Among these business strategies, product enhancements, agreements, and partnerships were the most widely adopted growth strategies by the players in the CTMS market.

Surgical Imaging Industry is Expecting Major Revolution in Near Future

Target Audience for this Study:

# C-arms manufacturers and distributors

# Healthcare institutions 

# Medical device vendors/service providers

# Research institutes

# Niche companies manufacturing imaging systems

# Research and consulting firms

# Venture capitalists

The surgical imaging market is expected to reach USD 1.63 Billion by 2022 from an estimated USD 1.25 Billion in 2017, at a CAGR of 5.5%.

The key factors driving the growth of this market are growing popularity of Flat Panel Detector C-arms (FPD C-arms) owing to advantages of FPDs over image intensifiers, reimbursement cuts on analog radiography systems, and increasing demand for minimally invasive procedures.

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=210534462

North America to dominate the market in 2017

North America is expected to account for the largest share of the surgical imaging market in 2017, followed by Europe, Asia Pacific (APAC), and the Rest of the World. The large share of this region can be attributed to a rising number of overuse sports injuries, and rising prevalence of CVD, along with the increasing number of cardiac arrest cases, and increase in the number of minimally invasive procedures performed in Canada.

However, Asia Pacific is expected to register the highest CAGR of 7.1% during the forecast period, owing to the rapid growth in geriatric population in Japan, healthcare reforms in China, improving healthcare infrastructure in India, and rising number of orthopedic and CVD procedures in Australia.

The following are the major objectives of the study:

# To describe and forecast the surgical imaging market, in terms of value, by technology, application, and region.

# To describe and forecast the market, by region–Asia Pacific (APAC), Europe, North America, and Rest of the World (RoW) along with their respective countries.

# To provide detailed information regarding major factors influencing market growth (drivers, restraints, opportunities, and challenges).

# To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market

# To study the complete value chain of surgical imaging.

# To analyze opportunities in the market for stakeholders by identifying the high-growth segments of the surgical imaging ecosystem.

# To strategically profile key players and comprehensively analyze their market position in terms of ranking and core competencies, along with detailing competitive landscape for market leaders.

# To analyze strategic approaches such as partnerships, agreements, alliances, collaborations, product launches, expansions, and acquisitions in the market.

The surgical imaging market is emerging and fragmented in nature with various regional and international players. In 2016, the surgical imaging market was dominated by a few large players and several small players. Players in this market compete with each other to deliver superior quality products that are technologically advanced and to provide well-regulated customer service functions. Major companies in this market are GE Healthcare (UK), Siemens AG (Germany), Koninklijke Philips (Netherlands), and Ziehm Imaging (Germany).

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=210534462

Major Market Developments:

# In 2017, Koninklijke Philips partnered with Government of Kenya and the United Nations to Establish the SDG (Sustainable Development Goals) Partnership Platform in Kenya to make primary healthcare more accessible.

# In 2017, Koninklijke Philips established its first innovation center in Moscow, Russia.

# In 2017, Siemens Received US FDA approval for its Cios Fusion, Cios Connect, and Cios Select.

# In 2017, Ziehm Imaging Launched the new version of Ziehm Vision FD with a complementary metal oxide semiconductor (CMOS) flat-panel detector and a new CMOS flat-panel detector which allows for display of smaller pixels in the same quality.

# In 2016, Shimadzu Corporation established an indirectly-owned subsidiary—Shimadzu Malaysia Sdn Bhd.

Agreements, collaborations, alliances, and partnerships were the key strategies adopted by players from 2014–2017. The players that adopted these strategies are Koninklijke Philips, Ziehm Imaging, GE Healthcare, Siemens, OrthoScan, Toshiba Medical Systems, and Medtronic. Koninklijke Philips accounted for a share of 38% of the total number of agreements, collaborations, alliances, and partnerships in the surgical imaging market. 

This high share of the company can be attributed to its increasing number of partnerships and collaborations with hospitals which are the primary end users of C-arms.

Read More Detailed Article@ https://bit.ly/2ZhD4m7

Human Liver Models Market - Growing Healthcare Market in the Asia Pacific and Latin America

Objectives of this Study:

# To define, measure, and describe the global human liver model market by type and region.

# To provide detailed information about the major factors influencing market growth (drivers, restraints, challenges, and opportunities).

# To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market.

# To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players.

# To forecast the size of market segments in North America, Europe, Asia Pacific, and RoW

The global human liver models market is expected to reach USD 2.56 Billion by 2022 from USD 1.35 Billion in 2017, at a CAGR of 13.6% during the forecast period (2017-2022).

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=171046468

The key factors driving the growth of this market include growing focus on developing alternatives for animal testing models, significant increase in research funding and venture capital investments for the development of liver models, growing initiatives to increase awareness about liver organoids, increasing research activities on liver organoids, increasing prevalence of non-alcoholic fatty liver disease, and growing need for the early detection of drug toxicity to minimize financial losses due to late-stage drug failure.

Target Audience:

# Pharmaceutical and biotechnology companies

# Chemical companies

# Cosmetic product manufacturers, suppliers, and distributors

# Healthcare providers and diagnostic laboratories

# Manufacturers of 3D Cell Culture products

# Food & beverage manufacturers

# Contract research organizations (CROs)

# Research institutes/universities

# Research and consulting firms

# Venture capitalists

North America held the largest share of the market in 2017

In 2017, North America accounted for the largest share of the human liver models market, followed by Europe.

The market for human liver models in this region is driven by the presence of a well-established life sciences industry, growing awareness about the organoids technology, favorable government initiatives, growing incidence of NAFLD, and unavailability of livers for transplantation, increased research spending, rising focus on tissue culture-based clinical diagnostics, and the availability of skilled professionals.

The human liver models market is emerging and fragmented in nature with various regional and international players. In 2016, the liver-on-a-chip and liver 3D bioprinting market was dominated by CN Bio (UK) and Organovo Holdings, Inc. (US), respectively.

The key players in the global human liver models market are Emulate (US), Ascendance Bio (US), HìREL (US), CN Bio (UK), Organovo (US), and Cyfuse Biomedical (Japan).

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=171046468

Major Growth Boosters for the Global Respiratory Care Devices Industry

The study involved 4 major activities in estimating the current market size for the respiratory care devices market. Exhaustive secondary research was done to collect information on the market as well as its peer and parent markets. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research.

The Global Respiratory Care Devices Market is projected to reach USD 31.8 billion by 2024 from USD 20.6 billion in 2019, at a CAGR of 9.1%.

Both the top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation were used to estimate the market size of segments and sub-segments.

Key Questions Addressed in the Report:

# Who are the top 10 players operating in the market?

# What are the drivers, restraints, opportunities, and challenges in the market?

# What are the industry trends as well as the current scenario in the market?

# What are the growth trends in the market at the segmental and overall market levels?

# How is the market performing in different regions across the globe?

Download PDF Brochure

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=368

The emergence of home healthcare has opened new growth avenues for the respiratory care devices market. Convenience and comfort in a home care environment, coupled with cost advantages, are the major factors driving the growth of the home healthcare market for respiratory care devices.

The major factor driving the growth of the respiratory care devices market is the high prevalence of respiratory diseases as a result of the rapid growth in the global geriatric population, high prevalence of tobacco smoking, urbanization and growing levels of pollution, and changing lifestyles.

Market Share Estimation:

The market shares for leading respiratory care devices companies was arrived at after a detailed assessment of their revenues from the respiratory care devices business by secondary data available through paid and unpaid sources. Owing to data limitations, in certain cases revenue share was arrived at after detailed assessment of the product portfolios of major companies and their respective sales performance. At each point, this data was validated through primary interviews with various industry experts.

Objectives of this study:

# To define, describe, segment, and forecast the global respiratory care devices market on the basis of product, indication, end user, and region.

# To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, opportunities, and industry-specific challenges).

# To analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the overall market.

# To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market players.

# To forecast the size of the market, in five main regions (along with major countries)—North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

# To profile key players in the global market and comprehensively analyze their core competencies and market shares.

# To track and analyze competitive developments such as mergers and acquisitions; new product/technology launches; expansions; collaborations and agreements; and R&D activities of the leading players in the global market.

Data Triangulation:

After arriving at the overall market size—using the market size estimation processes as explained above—the market was split into several segments and subsegments. In order to complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=368

The market in the Asia Pacific region is expected to be the fastest growing in 2019

While the respiratory care devices market in the APAC is relatively smaller than developed markets across North America and Europe, it is expected to grow at the highest rate. This can be attributed to the presence of high-growth markets such as Japan, China, India, South Korea, Taiwan, Australia, and Singapore.

In these countries, the rising geriatric population, growing per capita income, increasing investments in the healthcare industry by key market players, rising demand for cutting-edge technologies, and the expansion of private-sector hospitals to rural areas are major factors driving the growth of the respiratory care devices market. Low labor costs and the favorable regulatory environment in the region will also contribute.

The respiratory care devices market is fragmented in nature, with the top five players accounting for around half of the total market in 2018. There are other smaller and medium-sized players as well, operating at both global and regional levels. The leading market players are based across developed countries such as the US, the Netherlands, New Zealand, and Ireland.

However, in the past few years, smaller players have emerged, especially in the Asia Pacific market, competing with global players on the basis of price. Lucrative growth opportunities in the Asia Pacific market are increasing competition among market players. Companies are also focusing on R&D to add innovative technologies and products to their portfolios, which, in turn, helps them to strengthen their presence in respective markets.

The key players in the global respiratory care devices market are Philips Healthcare (Netherlands), ResMed Inc. (US), Medtronic plc (Ireland), Masimo Corporation (US), Fisher & Paykel Healthcare Corporation Limited (New Zealand), Chart Industries (US), Drager AG (Germany), Invacare Corporation (US), Getinge AB (Sweden), Air Liquide (France), Hamilton Medical AG (Switzerland), Vyaire Medical (US), GE Healthcare (US), Nonin Medical Inc. (US), Apex Medical Corp. (Taiwan), Smiths Group (UK), Omron Healthcare Inc. (US), Allied Healthcare Products, Inc. (US), Teleflex Incorporated (US), and DeVilbiss Healthcare LLC (US).

Read More Detailed Article@

https://www.marketsandmarkets.com/Market-Reports/respiratory-care-368.html

Animal Parasiticides Market - Expected Revenue Growth & Global Industry Future Forecasts

Target Audience:

# Animal Parasiticides Manufacturers

# Animal Parasiticides Distributors

# Animal Health Research & Development (R&D) Companies

# Government Associations

# Research and consulting firms

# Venture Capitalists and Investors

In 2014, ectoparasiticides accounted for the largest share of the global animal parasiticides market and this segment is expected to witness the highest growth over the next five years. The high growth in this segment can be attributed to the advantages offered by ectoparasiticides over other parasiticide formulations.

The animal parasiticides market witnessed healthy growth during the last decade and is expected to grow at a CAGR of 5.7% between 2015 and 2020 to reach 9.75 Billion by 2020.

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=258895412

The growth in this market is majorly attributed to factors such as rising animal healthcare expenditure, rising pet adoption, growing demand for animal-derived food products, increasing number of veterinary practitioners and their growing income levels in developed regions, increasing number of animal research activities along with growing research grants, and rising awareness about zoonotic diseases.

Critical questions the report answers:

# What are the geographic growth opportunities in the animal parasiticides market?

# How growing consolidation in the animal health industry will impact the animal parasiticides market in future?

Europe is the largest regional segment for animal parasiticides owing to the well-established animal healthcare market and growing R&D activities in this region. However, the market in the Asia-Pacific region is expected to grow at the highest CAGR, owing to rising pet adoption and increasing demand for animal-derived food products in India and China.

Some major mergers and acquisitions by Global Leaders are summarized below:

# In March 2015, Perrigo Company PLC (US) acquired Omega Pharma Invest N.V. (Belgium) for USD 4.61 million. This acquisition helped the company to enhance its presence across the globe.

# Zoetis, Inc. (US) acquired animal health assets of Abbott Laboratories (US) for USD 255 million, in February 2015. This acquisition expanded Zoetis’ companion animal product portfolio

# In January 2015, Eli Lilly and Company (US) acquired Novartis Animal Health (Switzerland). This acquisition helped the company strengthen its product portfolio and expanded its global commercial presence.

# In April 2014, Vetoquinol S.A. (France) acquired the animal health business of Bioniche Life Sciences Inc. (Canada). This acquisition helped Vetoquinol to leverage its existing animal healthcare product portfolio as well as its geographic presence.

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=258895412

Major Leaders:

The market players, namely, Sanofi (France), Bayer AG (Germany), and Zoetis, Inc. (U.S.) together accounted for the largest share of the animal parasiticides market and will continue to dominate the market between 2015 and 2020.

Rheometer & Viscometer Market - Emerging Technological Innovations

Years Considered for the Study:

# Base Year: 2017

# Forecast Period: 2018–2023

The demand for rheometers and viscometers across key markets is majorly driven by factors such as technology advancements; expansion of petrochemical and material manufacturing industries; growing stringency of the regulatory framework for product safety compliance in cosmeceutical, biotechnology, and pharmaceutical industries; rising public-private investments to support product innovation; and increasing burden of target diseases, globally. However, the high cost of viscometers and rheometers is expected to restrain the growth of this market during the forecast period.

The report studies the global rheometers and viscometers market over the forecast period from 2018 to 2023. The market is projected to reach USD 878.6 million by 2023 from USD 721.5 million in 2018, at a CAGR of 4.0%.

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=93584044

Objectives of the Study:

# To define, describe, and forecast the global viscometer market by product, sample type, end user, and region.

# To provide detailed information about the major factors influencing market growth (key drivers, restraints, opportunities, and industry-specific challenges).

# To strategically analyze micromarkets with respect to individual growth trends, prospects, and their contributions to the global viscometer market.

# To analyze market opportunities for stakeholders and provide details of the competitive landscape for key global players.

# To forecast the size of the market segments with respect to four main regions, namely, North America (US and Canada), Europe [Germany, France, the UK, and Rest of Europe (RoE)], Asia Pacific [China, India, Japan, and Rest of Asia Pacific (RoAPAC)], and the Rest of the World (RoW).

# To profile the key players active in the global rheometers and viscometers industry and comprehensively analyze their global revenue shares and core competencies.

# To track and analyze competitive market-specific developments such as product developments & commercialization, strategic mergers, market expansions, as well as agreements in the global rheometers and viscometers industry

North America is expected to dominate the rheometers and viscometers market in 2018.

Geographically, the market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. The large share of North America can be attributed to ongoing technological advancements in the field of rheometers & viscometers, the wide availability of rheometers and viscometers in the region (owing to the strong distribution networks of major product manufacturers in North America), and the strong presence of major device manufacturers.

Analysis of the market developments between 2014 and 2018 reveals that several growth strategies, such as product launches, expansions, mergers, and agreements were adopted by the market players to strengthen their product portfolios and maintain a competitive position in the rheometers and viscometers market. Among these business strategies, product launches and market expansions were the most widely adopted growth strategies by players in the market.

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=93584044

Major Stakeholders of the Global Industry:

# Rheometer and viscometer manufacturing companies

# Pharmaceutical, biotechnology, and cosmeceutical companies

# Petroleum manufacturers and petrochemical refineries

# Food processing companies and beverage manufacturers

# Chemical and material manufacturers

# Environmental testing, food testing, and forensic analysis laboratories

# Product sales and distribution companies

# Research and development companies

# Research laboratories and academic institutes

# Clinical research organizations (CROs)

# Government and non-governmental regulatory authorities

# Independent national and international associations

# Diagnostic and forensic testing laboratories

# Market research and consulting firms

Molecular Biology Enzymes Research - Global Industry Growth Dynamics

Growth in the molecular biology enzymes and kits & reagents market is driven by factors such as increased research activities and R&D investments in the life science industry, rising number of genome projects, technological advancements in the life science industry, and rising incidence of infectious diseases & genetic disorders. However, limited reimbursements for genetic testing is expected to restrain the growth of this market during the forecast period.

Target Audience:

# Molecular Biology Enzymes and Kits & Reagents Manufacturers and Vendors

# Associations Related to Molecular Biology Enzymes and Kits & Reagents

# Contract Research Organizations (CROs)

# Research Institutes and Academic Centers

# Pharmaceutical and Biopharmaceutical Companies

# Business Research and Consulting Service Providers

# Venture Capitalists

The global molecular biology enzymes and kits & reagents market is projected to reach USD 13.60 Billion by 2022 from USD 6.52 Billion in 2017, at a CAGR of 15.8% during the forecast period.

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=164131709

Based on end user, the market is segmented into academic & research institutes, hospitals & diagnostic centers, pharmaceutical & biotechnology companies, and other end users (contract research organizations (CROs), food & beverage companies, and forensic agencies).

The academic & research institutes segment is expected to command the largest share of the molecular biology enzymes and kits & reagents market in 2017. The large share of this segment can be attributed to the increasing research activities backed by funding from government and private organizations.

Objectives of the Study:

# To define and measure the global molecular biology enzymes and kits & reagents market on the basis of product, application, end user, and region.

# To identify key micromarkets and their drivers within the global molecular biology enzymes and kits & reagents market, which are expected to offer impressive growth opportunities in the coming years.

# To identify trends and opportunities for stakeholders in the market and provide details of the competitive landscape for major market leaders.

# To provide detailed information regarding the major factors influencing market growth (drivers, restraints, challenges, and opportunities).

# To forecast the size of the market segments with respect to four main regions, namely, North America (US and Canada), Europe (Germany, UK, France, and Rest of Europe), Asia Pacific (China, Japan, India, and Rest of APAC), and the Rest of the World (Latin America and Middle East & Africa)

# To analyze the market structure and profile key players in the global molecular biology enzymes and kits & reagents market and comprehensively evaluate their core competencies.

# To track and analyze competitive landscape such as market share analysis and competitive leadership

North America to dominate the market in 2017

In 2017, North America is expected to account for the largest share of the molecular biology enzymes and kits & reagents market, followed by Europe, Asia Pacific (APAC), and the Rest of the World (Latin America and the Middle East & Africa). Factors such as increasing research funding for genomics research, rising number of pharmaceutical and biotechnology companies, favorable reimbursement scenario for molecular diagnostics, and growing prevalence of target indications are contributing to the large share of North America.

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=164131709

In 2016, Thermo Fisher (US), Merck (Germany), and Illumina (US) held a share of 70% to 75% of the overall market.

The key players in the global molecular biology enzymes and kits & reagents market are Thermo Fisher (US), Merck (Germany), Illumina (US), QIAGEN (Netherlands), New England Biolabs (US), Promega (US), Agilent (US), Roche (Switzerland), Takara Bio (Japan), Bio Basic (Canada), Jena Bioscience (Germany), and Molecular Biology Resources (US).